Evidence method
Level · gp.fundamentals.debt_to_revenue
186.99% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
FBIO · Jun 30, 2026
Fortress Biotech, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001104659-26-095964General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-316.68% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
14.04% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
43.57% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-53.46% · CORE · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
15.38% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History7 statesHistory building
Period transition
What moved in the state?
- Previous
- 233.82%
- Current
- 186.99%
- Delta
- -46.83%
- Previous
- 1271.05%
- Current
- -316.68%
- Delta
- -1587.73%
- Previous
- 57.94%
- Current
- 43.57%
- Delta
- -14.36%
- Previous
- -48.25%
- Current
- -53.46%
- Delta
- -5.20%
- Previous
- 10.95%
- Current
- 15.38%
- Delta
- 4.43%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Pharmaceutical Preparations peers →Has State · Fortress Biotech, Inc. →Transitioned To · FBIO BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · FBIO CASH_GENERATION_DECREASED →Transitioned To · FBIO INVENTORY_PRESSURE_DECREASED →Transitioned To · FBIO PROFITABILITY_DECREASED →Transitioned To · FBIO SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.